A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

S

Sidney Kimmel Cancer Center at Thomas Jefferson University

Status and phase

Completed
Phase 2

Conditions

Multiple Myeloma
Hematological Malignancies
Hodgkin's Disease
Lymphoma
Leukemia

Treatments

Device: Matched Sibling Allogeneic Transplantation

Study type

Interventional

Funder types

Other

Identifiers

NCT01315132
08D.85
2007-61 (Other Identifier)

Details and patient eligibility

About

This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.

Full description

This research protocol has been developed for patients undergoing matched-sibling hematopoietic stem cell transplant (HSCT). The patients who are treated according to this 2 step allogeneic HSCT protocol will receive cyclophosphamide to induce in-vivo tolerization of both autologous and allogeneic lymphocytes, followed by an allogeneic CD34-selected HSCT. The primary research questions relate to immune reconstitution, incidence of GVHD, and relapse in patients who receive lymphocyte treatment of this type in allogeneic HSCT and how it impacts overall survival.

Enrollment

47 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. Patients will be considered high-risk if they have any of the following:

  • Age > 50 years
  • ECOG Performance status of <2
  • Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR; second or greater CR, 1st relapse; any ph+ ALL
  • CML 2nd chronic phase, accelerated phase, or blastic phase
  • MDS with IPS of Intermediate 2 or greater
  • Any myeloproliferative disorder
  • Hodgkin lymphoma: relapsed, refractory, or primary induction failure
  • Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not eligible for an autologous HSCT
  • Other conditions not listed will be assessed as high-risk by the PI
  • Patients must have a related donor who is either HLA-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci.

Patients must adequate organ function:

  • LVEF of >45%
  • DLCO (adjusted for hemoglobin) >45% of predicted
  • Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal
  • Creatinine clearance of > 60 ml/min
  • Patients must be willing to use contraception if they have childbearing potential
  • Able to give informed consent

Exclusion criteria

  • ECOG performance status of 3 or 4.
  • HIV positive
  • Active involvement of the central nervous system with malignancy
  • Psychiatric disorder that would preclude patients from signing an informed consent
  • Pregnancy
  • Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

47 participants in 1 patient group

Allogeneic Transplantation
Experimental group
Description:
Matched Sibling Allogeneic Transplantation
Treatment:
Device: Matched Sibling Allogeneic Transplantation

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems